long intergenic non-protein coding RNA 2102Genealiases: []
Q-omics provides the consensus-scored LINC02102 profile across patient tissues and cancer cell-line models. LINC02102 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LINC02102 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, LINC02102 RNA expression shows 16,735 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, LIHC, and THYM as cancer lineages where LINC02102 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02102 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02102 survival associations across molecular data types. LINC02102 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02102 RNA expression–survival associations across cancer types. High LINC02102 expression shows unfavorable associations in ACC, KIRP, KIRC, COAD and PRAD, but favorable associations in PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify ACC as the clearest survival context for LINC02102 RNA expression.
This table summarizes LINC02102 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02102. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02102 shows lower tumor expression in UCEC, THCA and STAD and higher tumor expression in LIHC, KIRC and HNSC. The LIHC box plot shows higher LINC02102 RNA expression in tumor versus normal tissue (log2 FC = +0.040, t-test p < 0.001).
This table shows molecular features associated with LINC02102 in patient tissues and cancer cell lines. In patient samples, LINC02102 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
